Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Janssen 63935937MDS3001: A Study to Evaluate Imetelstat (JNJ63935937) in Transfision-DependentSubjects with IPSS Low or Intermediate-I Risk Myelodysplastic Syndrom (MDS) that is Relapsed/ Refractory to Erythropoiesis-Stemulating Agent (ESA) Treatment
Brief Description  
Primary Part I: Evaluate efficacy and safety of imetelstat in transfusion dependent subjects with low/ intermediate-I risk MDS that is relapsed/ refratory to ESA treatment. Part I: To compare the efficacy, in terms of red blood cell (RBC) transfusion independence (TI), of imetelstat to placebo in tranfusion dependent subjects with low or intermediate-I risk MDS that is relapsed/ refractory to ESA treatment.
Who may be Eligible  
Please contact us for eligibility criteria.
Myeloid and Monocytic Leukemia
Start Date  
IRB Number  
Principal Investigator  
Grunwald, Michael Richard
Contact Name  
Mallory Tucker

For More Information, Contact  Mallory  , Tucker
Phone:  980-442-2011 Fax:    
Email:  Mallory.Rodgers@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204